The European Directorate for the Quality of Medicines & HealthCare (EDQM) has listed out deficiencies related to Biocon's API (active pharma ingredient or bulk drug) manufacturing site in Bengaluru after an inspection, the company said in a filing on Thursday. The Bengaluru-headquartered company said that while no deficiencies were marked as critical, one was listed as major.